Most doses of Eli Lilly's diabetes drug Mounjaro and weight-loss drug Zepbound would be in limited supply through the second quarter of this year due to increased demand, the U.S. Food and Drug Administration's website showed on Wednesday.
Item 1 of 2 An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. REUTERS/Brendan McDermidAn injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. REUTERS/Brendan McDermiddiabetes drug Mounjaro and weight-loss drug Zepbound would be in limited supply through the second quarter of this year due to increased demand, the U.S.
Increasing demand for a type of highly effective diabetes and weight-loss treatment known as GLP-1 agonists has led to supply constraints for drugmakers such as Lilly and Novo Nordisk
BLR CMPNY DIABET ENDOCR GEN HEA HECA HUMDIS OBESIT PHAG08 PHAR PHAR08 PHAR1 PHMR PUBL AMERS US NAMER RHPI:APPROVALS RHPI:REGULATORY MTPIX GOVACT GOVADM MEDREG PXP REGS RHPI:DRUG-DEVICE-TRIALS TOPNWS BACT BIZ CPROD DRUDEV GENHLT WEU SCANDV EUROP DK NORD EMEA FIN TOPCMB
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Most doses of Eli Lilly's Zepbound, Mounjaro in short supply through June, FDA saysThe insatiable demand for weight loss and diabetes drugs is still trouncing supply, even as Eli Lilly and Novo Nordisk work to increase production capacity.
Lire la suite »
Eli Lilly's weight-loss drug Zepbound could treat sleep apneaAn FDA green light could mean broader insurance coverage and a new treatment for a condition affecting 20 million Americans.
Lire la suite »
Eli Lilly's Zepbound shows promise as a sleep apnea treatment in late-stage trialsThe pharmaceutical giant plans to present the trial data at an upcoming medical conference and submit them to the U.S. Food and Drug Administration mid-year.
Lire la suite »
Eli Lilly’s weight loss drug Zepbound found to reduce sleep apnea, company saysBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Lire la suite »
Ozempic and Mounjaro have another benefit: treating inflammationA new study in mice shows that popular weight loss drugs can lower inflammation. What might this mean for the treatment of other diseases and neurodegenerative conditions?
Lire la suite »
Weight loss drug Zepbound may help people with obstructive sleep apnea, drugmaker saysZepbound, a popular weight loss drug, also seems to help people with obstructive sleep apnea, drugmaker Eli Lilly said Wednesday.
Lire la suite »